Key result
Elevated AFABP levels are independently linked to increased carotid intima-media thickness in type 2 diabetes.
Why the study?
Early detection of imminent atherosclerosis is critical to prevent complications in people with type 2 diabetes, but the relationship with adipocyte fatty acid-binding protein is not well defined.
Case-Control (n=80)
No
Plasma adipocyte fatty acid-binding protein (AFABP) is independently associated with carotid intima-media thickness in type 2 diabetes, suggesting its potential utility as a biomarker for subclinical atherosclerosis.
Answers are grounded in this paper and cite their sources.
AFABP may mark subclinical atherosclerosis in type 2 diabetes; hypothesis-generating and requires prospective validation before clinical adoption.
Objectives. Atherosclerosis contributes to higher mortality and morbidity in people with diabetes. Preventing future complications largely depends on the early detection of imminent atherosclerosis. This study aimed to explore the relationship between the subclinical atherosclerosis measured by carotid intima-media thickness (CIMT), ankle-brachial index (ABI), and circulating levels of adipocyte fatty acid-binding protein (AFABP) in individuals with type 2 diabetes mellitus (T2DM).
No takes yet. Share an insight, caveat, or question.
Shalash et al. (2026) conducted a case-control in Type 2 diabetes mellitus and subclinical atherosclerosis (n=80). Circulating adipocyte fatty acid-binding protein (AFABP) levels vs. Healthy controls / Lower AFABP levels was evaluated on Maximum carotid intima-media thickness (CIMT) (β 0.004, 95% CI 0.001-0.007, p=0.017). Circulating adipocyte fatty acid-binding protein (AFABP) levels were elevated in patients with type 2 diabetes and were independently associated with increased maximum carotid intima-media thickness (β=0.004, p=0.017).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: